Ⅰ-125粒子植入联合化疗和单纯化疗对胰腺癌疗效的荟萃分析

Curative effect of Ⅰ-125 particles implantation combined with chemotherapy and chemotherapy alone in pancreatic cancer: a Meta-analysis

目的分析评价Ⅰ-125粒子植入联合化疗和单纯化疗对胰腺癌的疗效。方法通过万方数据库、VIP、CNKI和Pub Med数据库收集有关文献。比较两种方法的有效率、临床受益率和生存率。结果纳入14篇研究文献,共859例患者,分为实验组：Ⅰ-125粒子植入联合化疗组,共411例;对照组：单纯化疗组,共448例。实验组有效率较对照组提高24%（95%CI：0.16~0.32,P〈0.00001）。实验组临床受益率较对照组提高23%（95%CI：0.17~0.30,P〈0.00001）。实验组与对照组相比,实验组的6个月生存率可提高22%（95%CI：0.10~0.34,P〈0.00001）,实验组的12个月生存率可提高27%（95%CI：0.15~0.39,P〈0.00001）。结论与单纯化疗相比,I-125粒子植入联合化疗能有效地提高胰腺癌治疗的有效率、临床受益率、生存率。

Objective To evaluate the curative effect of Ⅰ-125 particles implantation combined with chemotherapy and chemotherapy alone in pancreatic cancer. Methods The relevant literatures were collected by searching the databases of Wan Fang,VIP,CNKI and Pub Med. The effective rate,clinical benefit rate and survival rate of two methods were compared. Results A total of 14 literatures（ 859 patients） were included. They were divided into experimental group： Ⅰ-125 particles implantation combined chemotherapy,and control group： chemotherapy alone. Compared with control group,the effective rate was improved by 24% in experimental group（ 95% CI： 0. 16-0. 32,P〈0. 00001）,the clinical benefit rate were improved by 23% in experimental group（ 95% CI： 0. 17-0. 30,P〈0. 00001）,the6-month survival rate was improved by 22% in experimental group（ 95% CI： 0. 10-0. 34,P〈0. 00001）,and the12-month survival rate was improved by 27% in experimental group（ 95% CI： 0. 15-0. 39,P〈0. 00001）. Conclusion Compared with chemotherapy alone,the Ⅰ-125 particles implantation combined with chemotherapy can effectively improve effective rate,clinical benefit rate,and survival rate in the treatment of pancreatic cancer.